[8-K] Adverum Biotechnologies, Inc. Reports Material Event
Adverum Biotechnologies reported that it has issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1, and the cover page of the report is presented in Inline XBRL as Exhibit 104.
The filing explicitly states that the information in the report and the exhibit is not deemed "filed" under the Exchange Act and will not be incorporated by reference into other SEC filings. The 8-K itself does not include the underlying financial figures; the detailed results are contained in the furnished press release.
Adverum Biotechnologies ha comunicato di aver diffuso un comunicato stampa che annuncia i risultati finanziari per il trimestre chiuso il 30 giugno 2025 e fornisce un aggiornamento societario. Il comunicato è fornito come Exhibit 99.1, e la pagina di copertina del rapporto è presentata in Inline XBRL come Exhibit 104.
Il deposito dichiara espressamente che le informazioni contenute nel rapporto e nell'Exhibit non sono considerate "depositate" ai sensi dell'Exchange Act e non saranno incorporate per riferimento in altri documenti presentati alla SEC. L'8-K stesso non include le cifre finanziarie sottostanti; i risultati dettagliati sono contenuti nel comunicato fornito.
Adverum Biotechnologies informó que ha emitido un comunicado de prensa anunciando sus resultados financieros para el trimestre cerrado el 30 de junio de 2025 y proporcionando una actualización corporativa. El comunicado se suministra como Exhibit 99.1, y la portada del informe se presenta en Inline XBRL como Exhibit 104.
El registro declara explícitamente que la información del informe y del exhibit no se considera "presentada" conforme al Exchange Act y no será incorporada por referencia en otros documentos presentados ante la SEC. El Formulario 8-K en sí no incluye las cifras financieras subyacentes; los resultados detallados están contenidos en el comunicado suministrado.
Adverum Biotechnologies는 2025년 6월 30일로 종료된 분기의 재무 결과를 발표하고 회사 현황을 업데이트하는 보도자료를 발행했다고 보고했습니다. 해당 보도자료는 Exhibit 99.1로 제공되며, 보고서의 표지 페이지는 Inline XBRL로 Exhibit 104에 표시되어 있습니다.
해당 제출문서는 보고서 및 전시물에 포함된 정보가 Exchange Act에 따라 "제출된" 것으로 간주되지 않으며 다른 SEC 제출 서류에 자료로 포함되지 않을 것이라고 명시하고 있습니다. 8-K 자체에는 기초 재무 수치가 포함되어 있지 않으며, 상세한 결과는 제공된 보도자료에 담겨 있습니다.
Adverum Biotechnologies a annoncé avoir diffusé un communiqué de presse dévoilant ses résultats financiers pour le trimestre clos le 30 juin 2025 et fournissant une mise à jour d'entreprise. Le communiqué est fourni en tant que Exhibit 99.1, et la page de garde du rapport est présentée en Inline XBRL en tant que Exhibit 104.
Le dépôt précise explicitement que les informations contenues dans le rapport et dans l'exhibit ne sont pas considérées comme "déposées" en vertu de l'Exchange Act et ne seront pas incorporées par référence dans d'autres dépôts auprès de la SEC. Le formulaire 8-K lui‑même n'inclut pas les chiffres financiers sous-jacents ; les résultats détaillés figurent dans le communiqué fourni.
Adverum Biotechnologies teilte mit, dass ein Pressebericht veröffentlicht wurde, der die Finanzergebnisse für das am 30. Juni 2025 endende Quartal bekannt gibt und ein Unternehmensupdate enthält. Die Pressemitteilung wird als Exhibit 99.1 bereitgestellt, und die Titelseite des Berichts ist in Inline XBRL als Exhibit 104 dargestellt.
Die Einreichung stellt ausdrücklich fest, dass die Informationen im Bericht und im Exhibit gemäß dem Exchange Act nicht als "eingereicht" gelten und nicht durch Verweis in andere SEC-Einreichungen übernommen werden. Das 8-K selbst enthält nicht die zugrunde liegenden Finanzzahlen; die detaillierten Ergebnisse sind in der bereitgestellten Pressemitteilung enthalten.
- Press release furnished as Exhibit 99.1, providing the company's announced quarterly results and a corporate update.
- Inline XBRL cover page (Exhibit 104) included, supporting machine-readable disclosure formatting.
- No financial figures or metrics are included in the 8-K text itself; the filing relies on the furnished press release for substantive results.
- The company states the press release is not "filed" and will not be incorporated by reference, which limits statutory liability and may affect how the information is treated in subsequent filings.
Insights
TL;DR: Routine disclosure that furnishes a press release with quarter-end results; no financial data is included in the 8-K itself.
The filing is a standard Item 2.02 disclosure indicating the company furnished a press release announcing results for the quarter ended June 30, 2025. Because the 8-K contains no numeric results, its market impact depends entirely on the contents of Exhibit 99.1. The explicit statement that the materials are not "filed" and are not incorporated by reference limits statutory liabilities for the company. Investors must review the press release to assess material financial effects.
TL;DR: Administrative disclosure that confirms transparency in communicating quarter-end results but preserves legal protections by not 'filing' the release.
The company followed routine disclosure practices by furnishing a press release as Exhibit 99.1 and providing an Inline XBRL cover page as Exhibit 104. The filing's language that the release is not deemed "filed" and will not be incorporated by reference is a common legal posture to limit liability exposure. This is procedural rather than material without the press release contents being evaluated.
Adverum Biotechnologies ha comunicato di aver diffuso un comunicato stampa che annuncia i risultati finanziari per il trimestre chiuso il 30 giugno 2025 e fornisce un aggiornamento societario. Il comunicato è fornito come Exhibit 99.1, e la pagina di copertina del rapporto è presentata in Inline XBRL come Exhibit 104.
Il deposito dichiara espressamente che le informazioni contenute nel rapporto e nell'Exhibit non sono considerate "depositate" ai sensi dell'Exchange Act e non saranno incorporate per riferimento in altri documenti presentati alla SEC. L'8-K stesso non include le cifre finanziarie sottostanti; i risultati dettagliati sono contenuti nel comunicato fornito.
Adverum Biotechnologies informó que ha emitido un comunicado de prensa anunciando sus resultados financieros para el trimestre cerrado el 30 de junio de 2025 y proporcionando una actualización corporativa. El comunicado se suministra como Exhibit 99.1, y la portada del informe se presenta en Inline XBRL como Exhibit 104.
El registro declara explícitamente que la información del informe y del exhibit no se considera "presentada" conforme al Exchange Act y no será incorporada por referencia en otros documentos presentados ante la SEC. El Formulario 8-K en sí no incluye las cifras financieras subyacentes; los resultados detallados están contenidos en el comunicado suministrado.
Adverum Biotechnologies는 2025년 6월 30일로 종료된 분기의 재무 결과를 발표하고 회사 현황을 업데이트하는 보도자료를 발행했다고 보고했습니다. 해당 보도자료는 Exhibit 99.1로 제공되며, 보고서의 표지 페이지는 Inline XBRL로 Exhibit 104에 표시되어 있습니다.
해당 제출문서는 보고서 및 전시물에 포함된 정보가 Exchange Act에 따라 "제출된" 것으로 간주되지 않으며 다른 SEC 제출 서류에 자료로 포함되지 않을 것이라고 명시하고 있습니다. 8-K 자체에는 기초 재무 수치가 포함되어 있지 않으며, 상세한 결과는 제공된 보도자료에 담겨 있습니다.
Adverum Biotechnologies a annoncé avoir diffusé un communiqué de presse dévoilant ses résultats financiers pour le trimestre clos le 30 juin 2025 et fournissant une mise à jour d'entreprise. Le communiqué est fourni en tant que Exhibit 99.1, et la page de garde du rapport est présentée en Inline XBRL en tant que Exhibit 104.
Le dépôt précise explicitement que les informations contenues dans le rapport et dans l'exhibit ne sont pas considérées comme "déposées" en vertu de l'Exchange Act et ne seront pas incorporées par référence dans d'autres dépôts auprès de la SEC. Le formulaire 8-K lui‑même n'inclut pas les chiffres financiers sous-jacents ; les résultats détaillés figurent dans le communiqué fourni.
Adverum Biotechnologies teilte mit, dass ein Pressebericht veröffentlicht wurde, der die Finanzergebnisse für das am 30. Juni 2025 endende Quartal bekannt gibt und ein Unternehmensupdate enthält. Die Pressemitteilung wird als Exhibit 99.1 bereitgestellt, und die Titelseite des Berichts ist in Inline XBRL als Exhibit 104 dargestellt.
Die Einreichung stellt ausdrücklich fest, dass die Informationen im Bericht und im Exhibit gemäß dem Exchange Act nicht als "eingereicht" gelten und nicht durch Verweis in andere SEC-Einreichungen übernommen werden. Das 8-K selbst enthält nicht die zugrunde liegenden Finanzzahlen; die detaillierten Ergebnisse sind in der bereitgestellten Pressemitteilung enthalten.
FAQ
What did Adverum (ADVM) disclose in this 8-K?
Does the 8-K include the company's financial results?
Is the press release considered "filed" with the SEC?
Where can I find the press release mentioned in the 8-K?
Who signed the Form 8-K for Adverum?
